RELATING TO STATE AFFAIRS AND GOVERNMENT -- RHODE ISLAND, BIOTECHNOLOGY REGULATORY SANDBOX ACT
H7337 creates the Rhode Island Biotechnology Regulatory Sandbox Act and places the program within the Department of Business Regulation (DBR). The sandbox would let approved biotechnology companies, research institutions, or other entities test innovative biotechnology products or services in Rhode Island with temporary, limited exemptions from certain state licensing, authorization, and regulatory requirements. Applicants must describe the product or service, identify the laws they want waived during testing, explain consumer benefits and risks, and show they have the personnel, funding, technical capacity, and consumer-protection measures needed to conduct the test.
The bill sets a structured approval and oversight process. DBR must consult with relevant state agencies and coordinate with federal frameworks, including the FDA, USDA, and EPA, before admitting a participant. Approved participants may test for up to 24 months, with a possible extension of up to 12 additional months to obtain required licensure or authorization. Participants must provide quarterly reports, maintain records, notify the department if a test fails, and comply with consumer disclosure requirements. The department may terminate participation for noncompliance, unethical conduct, or public safety concerns, and it must report annually to the General Assembly on participants, program effectiveness, and possible regulatory reforms.
If enacted, the bill would add a new chapter to Title 42 of the General Laws and give DBR new authority to administer a biotechnology regulatory sandbox. It would temporarily relax certain state regulatory barriers for qualifying biotechnology innovations while preserving exclusions for human genetic modification prohibitions, necessary environmental protections, and ethical standards for human or animal research. The bill also requires consumer disclosures, reporting, recordkeeping, and a formal exit pathway back into ordinary licensing or authorization requirements, thereby creating a controlled pilot framework rather than a permanent exemption from regulation.
Based on the bill text and the absence of recorded committee testimony or votes, the overall sentiment appears to be pro-innovation and pro-economic development, with an emphasis on allowing biotechnology products and services to be tested in Rhode Island under supervised conditions. The structure of the bill suggests an effort to balance regulatory flexibility with consumer protection, public safety, and agency oversight. No formal opposition, amendments, or recorded vote history is provided in the materials supplied.
The main points of potential contention are the scope of regulatory relief, the department’s broad discretion to deny applications, and the possibility that competitors’ participation may be considered in reviewing new applicants. Other likely concerns include consumer risk, liability exposure, whether waiving certain licensing rules could weaken oversight, and how the sandbox would interact with federal and state rules. The bill attempts to address these concerns through disclosure requirements, reporting obligations, agency consultation, and carve-outs for sensitive areas such as human genetic modification and environmental protections.